Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts.

MLA

Suzuki, Yoshihide, et al. “Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts.” Frontiers in Chemistry, vol. 9, Nov. 2021, p. 766107. EBSCOhost, https://doi.org/10.3389/fchem.2021.766107.

APA

Suzuki, Y., Ichinohe, K., Sugawara, A., Kida, S., Murase, S., Zhang, J., Yamada, O., Hattori, T., Oshima, Y., & Kikuchi, H. (2021). Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. Frontiers in Chemistry, 9, 766107. https://doi.org/10.3389/fchem.2021.766107

Chicago

Suzuki, Yoshihide, Keisuke Ichinohe, Akihiro Sugawara, Shinya Kida, Shinya Murase, Jing Zhang, Osamu Yamada, Toshio Hattori, Yoshiteru Oshima, and Haruhisa Kikuchi. 2021. “Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts.” Frontiers in Chemistry 9 (November): 766107. doi:10.3389/fchem.2021.766107.